The role of host genes IFNAR2 and TYK2 in COVID-19 disease severity

Medical News: How your genes may influence your response to COVID-19
As the world continues to navigate the ongoing impact of COVID-19, scientists are still working to understand why the disease affects people differently. While some recover quickly, others face severe or even fatal consequences. In a groundbreaking study, researchers have uncovered crucial links between specific genes and the severity of COVID-19 outcomes. This new research, conducted by scientists from Mazandaran University of Medical Sciences, Tehran University of Medical Science, and Kyorin University, reveals that two particular genes, IFNAR2 and TYK2, may hold the key to understanding who is most at risk. This Medical News report sheds light on the findings, explaining how these genes interact with the virus and influence the immune response, potentially paving the way for new therapeutic approaches.


The role of host genes IFNAR2 and TYK2 in COVID-19 disease severity

What Are IFNAR2 and TYK2?
At the heart of this research are two genes - IFNAR2 and TYK2 - which play significant roles in the body’s immune system. The IFNAR2 gene encodes a receptor for type I interferons, proteins crucial for the body’s defense against viral infections. When the body detects a viral invader, such as SARS-CoV-2 (the virus that causes COVID-19), type I interferons activate this receptor, triggering a cascade of immune responses aimed at stopping the virus in its tracks. On the other hand, TYK2 is involved in signaling processes that help modulate the body’s response to interferons and other cytokines.
 
Recent studies have suggested that variations in these genes can affect how well an individual’s immune system responds to COVID-19. For example, some people may have genetic mutations that limit the effectiveness of the IFNAR2 receptor, weakening the body’s antiviral defenses. Meanwhile, alterations in TYK2 expression could impact the inflammatory response, potentially leading to the dangerous overreaction known as a "cytokine storm."
 
The Study: Understanding the Genetic Connection
The research team behind this new study aimed to explore the precise role of IFNAR2 and TYK2 in COVID-19 pathology. Their work involved analyzing data from genome-wide association studies (GWAS) and conducting molecular-level experiments to assess how these genes were expressed in individuals infected with the virus. They found that certain variations in these genes were strongly linked to severe outcomes in COVID-19 patients.
 
One key finding was that increased expression of the IFNAR2 gene correlated with a lower likelihood of developing critical COVID-19. In simple terms, people with higher levels of IFNAR2 expression were less likely to experience severe symptoms. The researchers discovered that when type I interferons bind to the IFNAR2 receptor, the immune system kicks into high gear, producing proteins that help block the virus from replicating and spreading.
 
However, genetic variations, including specific polymorphisms in IFNAR2, can reduce t he receptor's expression or affect its ability to bind interferons. In this article, the researchers noted that individuals with these variations faced a greater risk of severe disease and even death, due to the reduced ability to mount an effective antiviral response.
 
TYK2: Another Piece of the Puzzle
TYK2, a gene involved in regulating the IFNAR2 signaling pathway, also plays a critical role in determining how the body responds to COVID-19. The study revealed that alterations in TYK2 expression were associated with an increased risk of severe outcomes, as these genetic changes could impair the immune response.
 
Interestingly, the researchers observed that individuals with lower levels of TYK2 expression had a decreased ability to control viral replication. This gene works hand-in-hand with IFNAR2, so when either gene is not functioning optimally, the body’s ability to defend itself against the virus is compromised.
 
A Deeper Dive into the Findings
The researchers behind this study conducted an in-depth analysis of how these genes affect COVID-19 outcomes. They found that polymorphisms in the IFNAR2 gene - such as rs2236757 and rs3153 - alter the structure and function of the receptor, making it less effective at binding to interferons. As a result, people with these genetic variations have a higher risk of severe disease and mortality.
 
Furthermore, the study highlighted the importance of TYK2 in regulating the immune response. Variations in this gene can lead to changes in how the body responds to interferons, potentially reducing the effectiveness of the antiviral defense system. The researchers noted that decreased expression of TYK2 was strongly correlated with more severe COVID-19 outcomes, as the immune system struggled to control the virus’s spread.
 
One of the most striking aspects of this study was the discovery that in severe cases of COVID-19, there were significantly lower levels of interferon compared to other viral infections. This reduction in interferon levels may be linked to the altered expression of IFNAR2 and TYK2, further underscoring the importance of these genes in determining the course of the disease.
 
The Broader Implications
The findings of this study have significant implications for the future of COVID-19 treatment. By understanding the genetic factors that contribute to severe disease outcomes, researchers hope to develop targeted therapies that can enhance the immune response in individuals who are genetically predisposed to severe COVID-19.
 
For example, treatments that boost IFNAR2 expression or restore proper TYK2 signaling could help improve the body’s ability to fight off the virus. Additionally, screening for these genetic variations could help identify individuals who are at higher risk of severe disease, allowing for earlier intervention and more personalized treatment strategies.
 
Conclusion
This study represents an important step forward in understanding the genetic factors that contribute to the severity of COVID-19. By identifying the critical roles that IFNAR2 and TYK2 play in the body’s immune response to the virus, researchers have opened the door to new therapeutic possibilities.
 
In conclusion, this research underscores the complexity of the immune system’s response to COVID-19. Genetic variations in IFNAR2 and TYK2 can have a profound impact on how well the body is able to mount a defense against the virus. These findings could pave the way for new treatments that target these genes, helping to protect those who are most vulnerable to severe disease.
 
The study findings were published in the peer-reviewed journal: Frontiers in Immunology.
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1462628/full
 
For the latest COVID-19 News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/covid-19-genetics-study-finds-that-cd147-rs8259t-a-variant-is-a-risk-factor-for-covid-19-in-the-mexican-population
 
https://www.thailandmedical.news/news/study-identifies-seven-hub-genes-ifi44,-ifi44l,-mx1,-oas3,-usp18,-ifi27-and-isg15-as-potential-therapeutic-targets-for-sars-cov-2-omicron-infections